7 hours ago
1
Kitsawet Saethao
- Sanofi (NASDAQ:SNY) said that a recent U.S. study found that its Beyfortus (nirsevimab) injection successfully met its main goals, showing that it helps protect infants from respiratory syncytial virus (RSV) illness.
- The research revealed an 87% decrease in RSV cases among healthy, full-term
English (US) ·